MCRB Stock Analysis: Buy, Sell, or Hold?
MCRB - Seres Therapeutics, Inc.
$5.03
0.20 (4.14%)
▲
5d:
+3.71%
30d:
-35.01%
90d:
-33.9%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 05, 2026
TODAY
Get Alerted When MCRB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: MCRB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: MCRB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: MCRB is currently trading at $5.03, which is considered slightly low relative to its 30-day fair value range of $4.79 to $7.21.
Technical Outlook: Technically, MCRB is in a strong downtrend. Immediate support is located at $4.59, while resistance sits at $5.44. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: MCRB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (4th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $17.00 (+238.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MCRB is in a strong downtrend. Immediate support is located at $4.59, while resistance sits at $5.44. The stock is showing strong short-term momentum, up 4.1% recently.
Market Sentiment: MCRB has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (4th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $17.00 (+238.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$4.79 -
$7.21
Company Quality Score
44/100
(HOLD)
Options IV Signal
4th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 4th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.1%)
- BULLISH: Trading 238.0% below Wall St target ($17.00)
Trading Range Analysis
30-Day Trading Range
$4.79 -
$7.21
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$0.82
(16.4%)
Support & Resistance Levels
Support Level
$4.59
Resistance Level
$5.44
Current Trend
Strong Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.77
Wall Street Target
$17.00
(+238.0%)
Revenue Growth (YoY)
-93.4%
Earnings Growth (YoY)
-91.9%
Share & Embed Analysis
Last updated: August 04, 2026 5:36 AM ET
Data refreshes hourly during market hours. Next update: 6:36 AM
Data refreshes hourly during market hours. Next update: 6:36 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MCRB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 53 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$386 | 43 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$557 | 49 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 54 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
Advanced MCRB Option Strategies
Professional options setups generated by AI based on today's MCRB price and gamma walls.
